Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSE: Ferric carboxymaltose in COPD patients with iron deficiency
2017-003659-52Phase 4Terminated
- Sponsor
- António Robalo Nunes
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose in chronic obstructive pulmonary disease (COPD) and iron deficiency anemia (IDA) (2 arms), sponsored by António Robalo Nunes. Primary endpoint: Proportion of patients with ≥25-meter increase in 6-minute walk test distance. Started Feb 2018; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
chronic obstructive pulmonary disease (COPD)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2017-003659-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003659-52.